Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
23.32
40.7
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BIBCL stock under the Base Case scenario is 4.55 INR. Compared to the current market price of 23.32 INR, Bharat Immunologicals and Biologicals Corporation Ltd is Overvalued by 80%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bharat Immunologicals and Biologicals Corporation Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BIBCL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Bharat Immunologicals and Biologicals Corporation Ltd
Balance Sheet Decomposition
Bharat Immunologicals and Biologicals Corporation Ltd
Current Assets | 327.1m |
Cash & Short-Term Investments | 89.1m |
Receivables | 100.3m |
Other Current Assets | 137.8m |
Non-Current Assets | 1.6B |
Long-Term Investments | 92.8m |
PP&E | 1.2B |
Other Non-Current Assets | 309.2m |
Current Liabilities | 990.5m |
Accounts Payable | 7.8m |
Short-Term Debt | 708.6m |
Other Current Liabilities | 274.1m |
Non-Current Liabilities | 103.7m |
Long-Term Debt | 35m |
Other Non-Current Liabilities | 68.7m |
Earnings Waterfall
Bharat Immunologicals and Biologicals Corporation Ltd
Revenue
|
76.5m
INR
|
Cost of Revenue
|
-218.1m
INR
|
Gross Profit
|
-141.6m
INR
|
Operating Expenses
|
-61.2m
INR
|
Operating Income
|
-202.8m
INR
|
Other Expenses
|
18m
INR
|
Net Income
|
-184.8m
INR
|
Free Cash Flow Analysis
Bharat Immunologicals and Biologicals Corporation Ltd
INR | |
Free Cash Flow | INR |
BIBCL Profitability Score
Profitability Due Diligence
Bharat Immunologicals and Biologicals Corporation Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Bharat Immunologicals and Biologicals Corporation Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
BIBCL Solvency Score
Solvency Due Diligence
Bharat Immunologicals and Biologicals Corporation Ltd's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Score
Bharat Immunologicals and Biologicals Corporation Ltd's solvency score is 22/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIBCL Price Targets Summary
Bharat Immunologicals and Biologicals Corporation Ltd
Dividends
Current shareholder yield for BIBCL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bharat Immunologicals & Biologicals Corp. Ltd. is a biotechnology company, which engages in the manufacture and market of pharmaceutical products. The company is headquartered in Bulandshahr, Uttar Pradesh. The firm is primarily engaged in the manufacture of Oral polio Vaccine, Zinc Tablets, Diarrhea management Kit and BIB Sweet Tablets. The company is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The firm is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). The company is also diversified into Plasma-derived medicines and Oral Cholera vaccines. The firm's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.
Contact
IPO
Employees
Officers
The intrinsic value of one BIBCL stock under the Base Case scenario is 4.55 INR.
Compared to the current market price of 23.32 INR, Bharat Immunologicals and Biologicals Corporation Ltd is Overvalued by 80%.